Background: Nitric oxide (NO) has been shown to decrease 
INTRODUCTION
Arterial wall injury initiates a cascade of events, including platelet and inflammatory cell recruitment resulting in local mitogen release, that culminates in smooth muscle migration and proliferation (reviewed in Ref. 1) . This sequence of events is thought to be important in the pathogenesis of intimal hyperplasia associated with restenosis as well as atherosclerosis. Such a predictable response to vascular injury may compro-mise the success of angioplasty and surgical bypass for obstructive vascular lesions. Many current experimental efforts focus on methods to minimize the local proliferative process and reduce neointima formation. Potentially efficacious agents under investigation include cytotoxic drugs, angiotensin-converting enzyme inhibitors (2) , antisense oligonucleotides to block gene expression (3) , and gene transfer to promote the local synthesis of antiproliferative agents (4, 5) . If one could inhibit the proliferative response of the injured tissue, the incidence of restenosis might be significantly reduced.
A vital component of normal vascular ho-212 Molecular Medicine, Volume 2, Number 2, March 1996 meostasis is endothelium-derived nitric oxide (NO) . Vascular properties of nitric oxide (NO) include vasodilation (6, 7) , prevention of platelet adhesion and activation (8) , inhibition of smooth muscle proliferation (9) , and prevention of leukocyte-endothelial interactions (10) . Under physiologic conditions, NO is derived from the endothelial constitutive NO synthase (ecNOS or Type III NOS), which synthesizes small quantities of NO in a calcium-and calmodulin-dependent fashion (1 1, 12) . Endothelial injury and dysfunction are common features of a number of disease processes, and the loss of NO synthetic capacity may contribute to the pathologic changes. For example, hypertensive states have been identified in which endothelium-derived NO is deficient, resulting in pathophysiologic alterations in the blood vessel (13, 14) . NO deficiencies may also exist at sites of injury incurred by angioplasty or surgical procedures (15, 16) .
Others have reported evidence that increasing serum levels of the NOS substrate L-arginine (17, 18) attenuates neointima formation at sites of vascular injury. Recent results in a rat carotid injury model indicates restoring ecNOS activity at the site of injury with liposome-mediated transfection prevents neointimal hyperplasia and preserves vasoreactivity (19) . Another approach to increase local NO levels is through the transfer of a different NOS isoform, the 
MATERIALS AND METHODS

Construction of Retroviral Vectors
The human hepatocyte iNOS cDNA measuring 4145 bp in length was cloned in our laboratory as previously described (22) (26) . Viral supernatants were collected 72 hr after transfection and used to infect CRIP cells (27) the BCA protein assay. Some supernatants were also assessed for total NO2 and NO3 levels with a standardized HPLC assay utilizing an in-line column containing copper-coated cadmium as previously described (34) .
Arterial Organ Culture Femoral arteries were collected from anesthesized (sodium pentobarbital, 4 mg/kg) domestic pigs through bilateral groin incisions and immediately immersed into sterile phosphate buffered saline. The adventitia was gently dissected free, and some vessels were uniformly injured with a 4-French balloon catheter inflated to 10 atmospheres for 30 sec. All arteries were opened along the long axis, divided into 1-cm-long sections, and cultured in DMEM, 20% FCS, 100 U/ml penicillin, 100 jig/ml streptomycin, and 4 mM L-glutamine at 37°C as previously described (35 (Fig. 3) demonstrated the presence of iNOS protein in SPAEC-DFGiNOS cytosolic preparations, similar in mobility to endogenous human iNOS protein in cytosol from cytokine treated human hepatocytes (31) . NO production (representing 40% of total nitrogen oxide metabolites) by uninfected and BaglacZ-and DFGiNOS-infected SPAEC is summarized in Fig. 4 The expression of ecNOS is important to normal endothelial function. Therefore, the effect of sustained supraphysiologic NO synthesis by iNOS on endogenous ecNOS expression in these endothelial cells was also examined. Northern blot analysis (Fig. 5A) (Fig. 7A , top or bottom panels, respectively) in the infected arterial segments showed an estimated infection efficiency of 0.5-1%. The majority of cells expressing either enzyme were found to be located in the superficial neointimal region. While the viral infection efficiency appeared extremely low, earlier attempts to infect similar arterial segments not subjected to prior injury resulted in no detectable transgene expression. Because of this low efficiency, transgene expression was further confirmed by reverse transcriptase PCR amplification for human iNOS message. The predicted 316-bp iNOS PCR product was strongly detected only in DFGiNOS-infected vessel segments (Fig.  7B) The effect of iNOS gene transfer on myointimal proliferation in response to injury was evaluated and is summarized in Fig. 8A . Balloon catheter injury resulted in a significant increase in myointimal thickness, as determined by rhodamine phalloidan staining (Fig. 8B) , in both injury alone or injury followed by infection with MFGlacZ (myointimal thicknesses of 153 and 147% of uninjured controls, respectively). In contrast, the proliferative response to balloon injury in arteries subsequently infected with DFGiNOS was markedly attenuated and essentially indistinguishable from uninjured vessels. The inhibitory effect of DFGiNOS infection on myointimal thickening was completely abrogated by L-NMA administration, indicating the effect was dependent on NO synthesis. These results show successful reduction in myointimal hypertrophy following balloon catheter-induced arterial injury with human iNOS gene transfer despite low gene transfer efficiency.
DISCUSSION
This study represents our initial investigation into the feasibility and biologic effectiveness of vascular human iNOS gene transfer. We con- The biologic effect of human iNOS gene transfer on myointimal thickening was assessed in an ex vivo organ culture system. Balloon catheter-induced arterial injury elicits a characteristic tissue response consisting of smooth muscle migration, proliferation, and augmented extracellular matrix deposition. These events culminate in neointima formation and myointimal thickening. An in vitro model of vascular injury using rabbit aorta with subsequent gene transfer has been established (35) and has been shown to be useful in studying the effect of various gene products on intimal hyperplasia. We adapted this model to balloon catheter-injured porcine femoral arteries where a similar injury response was reproducibly created. Human iNOS gene transfer to these injured vessel segments was accomplished with retroviral infection 5 days post-injury, a time period associated with near-maximal smooth muscle cell proliferation (35) . Because of the absolute requirement for cellular replication for successful retroviral integration, infection of uninjured vessels or vessels immediately following injury resulted in poor infection efficiencies. By delaying infection until maximal cellular pro- liferation was achieved, our infection efficiency was improved to 1%. While this still represents a small number of cells expressing the transgene, NO synthesis and cGMP production were nonetheless significantly elevated. Despite the low efficiency of gene transfer, the level of iNOS expression and NO synthesis was sufficient to eliminate the myointimal hyperplasia associated with the vascular injury response. It is not surprising that sufficient levels of NO were synthesized by the few infected cells to dramatically influence cGMP and myointimal proliferation in vitro. NO is highly diffusable in solution and creates a "field effect" around secreting cells (42) . In the absence of hemoglobin, NO would be expected to have profound effects on neighboring cells. Whether such an extensive field effect will be available in vivo remains to be determined.
The mechanism by which NO impacts on myointimal thickening and which aspects of smooth muscle migration, proliferation, and extracellular matrix deposition that iNOS gene transfer influences remains to be elucidated. While higher levels of NO release significantly reduced [3H]-thymidine incorporation (9), our early observations indicate that the levels of NO generated by the DFGiNOS-infected arterial segments have minimal effects on smooth muscle Support for both the importance of NO for restoring normal structure and function of the blood vessel wall and for the therapeutic use of NOS gene transfer to reduce restenosis comes from von der Leyen et al. (19) . These authors show inhibition of intimal hyperplasia and restoration of vasoreactivity in a rat carotid artery injury model using liposome-mediated transfer of the bovine endothelial cNOS. In clinical practice, high efficiency vascular gene transfer may be difficult due to the dangers of prolonged vascular occlusion required by most gene transfer techniques. Our studies suggest that iNOS may have some advantages over ecNOS. Because iNOS activity is not dependent on increases in intracellular calcium levels for activation, the activity of the expressed enzyme will be dependent only on cofactor and substrate availability, as shown by our studies in cells and tissue, and not agonists to increase intracellular free calcium. Furthermore, because the activity of iNOS is much greater than ecNOS, the transfer efficiency required for production of therapeutic levels of NO may be much lower than for ecNOS. With continued, rapid advances in vector and delivery system development for vascular gene therapy, specific approaches for adequate and safe transfer of NOS to blood vessels may soon be a reality.
